Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Edgewise Therapeutics Inc (EWTX)

Edgewise Therapeutics Inc (EWTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,758,703
  • Shares Outstanding, K 93,399
  • Annual Sales, $ 0 K
  • Annual Income, $ -100,160 K
  • 60-Month Beta 0.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.21
Trade EWTX with:

Options Overview Details

View History
  • Implied Volatility 246.55% ( +38.03%)
  • Historical Volatility 66.35%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 246.55% on 09/16/24
  • IV Low 3.66% on 12/14/23
  • Put/Call Vol Ratio 1.12
  • Today's Volume 2,483
  • Volume Avg (30-Day) 1,146
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 21,051
  • Open Int (30-Day) 9,221

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.38
  • Number of Estimates 5
  • High Estimate -0.34
  • Low Estimate -0.42
  • Prior Year -0.41
  • Growth Rate Est. (year over year) +7.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.60 +1.57%
on 09/16/24
21.04 -19.87%
on 08/22/24
-1.59 (-8.62%)
since 08/16/24
3-Month
15.02 +12.25%
on 08/05/24
23.50 -28.26%
on 07/15/24
-0.65 (-3.71%)
since 06/14/24
52-Week
5.12 +229.30%
on 11/10/23
23.50 -28.26%
on 07/15/24
+10.44 (+162.62%)
since 09/15/23

Most Recent Stories

More News
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street

Analysts have high hopes for these three innovation companies in 2024.

BEAM : 25.62 (-2.59%)
EWTX : 16.86 (-10.46%)
GLUE : 5.62 (-7.57%)
Edgewise Therapeutics to Present at Upcoming Investor Conferences

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle...

EWTX : 16.86 (-10.46%)
Edgewise Therapeutics Announces Journal of Clinical Investigation Publication of Key Preclinical Data Linking Modulation of Fast Skeletal Muscle Contraction to Protection of Skeletal Muscle in Models of Duchenne Muscular Dystrophy (DMD)

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle...

EWTX : 16.86 (-10.46%)
Edgewise Therapeutics to Present at the Stifel 2023 CNS Days on March 28, 2023

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle...

EWTX : 16.86 (-10.46%)
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2023 Annual MDA Clinical and Scientific Conference

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle...

EWTX : 16.86 (-10.46%)
Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for individuals with devastating muscle...

EWTX : 16.86 (-10.46%)
Edgewise Therapeutics to Present at the Cowen 43rd Annual Health Care Conference on March 8, 2023

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle...

EWTX : 16.86 (-10.46%)
Edgewise Therapeutics Announces Upcoming Presentation at the American College of Cardiology's 72nd Annual Scientific Session Together with World Congress of Cardiology

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle...

EWTX : 16.86 (-10.46%)
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle...

EWTX : 16.86 (-10.46%)
Edgewise Therapeutics to Present at the SVB Securities Global Biopharma Conference on February 14, 2023

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle...

EWTX : 16.86 (-10.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Edgewise Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing orally bioavailable, small molecule therapies for rare muscle disorders. Edgewise Therapeutics Inc. is based in Boulder, United States.

See More

Key Turning Points

3rd Resistance Point 20.92
2nd Resistance Point 20.01
1st Resistance Point 18.43
Last Price 16.86
1st Support Level 15.94
2nd Support Level 15.03
3rd Support Level 13.45

See More

52-Week High 23.50
Last Price 16.86
Fibonacci 61.8% 16.48
Fibonacci 50% 14.31
Fibonacci 38.2% 12.14
52-Week Low 5.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar